Elan reports positive Tysabri results on slowing the progression of MS disability but mixed results on PML brain disease
Sep 22nd, 2008 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan, the Irish drugs firm, says that analysis from phase three trials of its MS drug Tysabri shows that the drug increases the probability of patients achieving sustained improvement in physical disability over two years. The firm reported no new cases of the PML brain disease. However, one patient with the disease is reportedly recovering and one deteriorating further.